First, the protective effect of PCSK9 inhibition on atherosclerosis in patients with SLE should be evaluated because atherosclerosis is highly prevalent in SLE patients and PCSK9 inhibition has been suggested to be beneficial for this condition. Here, PCSK9 is linked to systemic lupus erythematosus.